Ticagrelor is an oral direct-acting antiplatelet agent that inhibits P2Y12 receptor
activation. The PLATO study showed that ticagrelor significantly reduced the composite
outcome of vascular death, myocardial infarction (MI) or stroke compared to clopidogrel
in patients with acute coronary syndrome (ACS) [
[1]
]. Post hoc analysis of the PLATO study demonstrated a lower mortality rate of pneumonia
and sepsis in the ticagrelor group [
[2]
]. Moreover, a recent study found that ticagrelor possessed direct bactericidal activity
against gram positive cocci (GPC) [
[3]
]. In mice, the conventional oral antiplatelet dosage of ticagrelor (3 mg/kg loading
dose, then 1.5 mg/kg twice daily) could inhibit the growth and dissemination of Staphylococcus aureus [
[3]
]. The present study was to assess whether ticagrelor treatment in patients with acute
MI would be associated with fewer severe infectious events that need admission compared
with clopidogrel users during follow-up after discharge.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med. 2009; 361: 1045-1057
- Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.Platelets. 2014; 25: 517-525
- Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant gram positive bacteria.JAMA Cardiol. 2019; 4: 596-599
- Short- and long-term cause of death in patients treated with primary PCI for STEMI.J Am Coll Cardiol. 2014; 64: 2101-2108
- Mortality following first-time hospitalization with acute myocardial infarction in Norway, 2001-2014: time trends, underlying causes and place of death.Int J Cardiol. 2019; 294: 6-12
- Protective activity of ticagrelor against bacterial infection in acute myocardial infarction patients.Eur J Intern Med. 2019; 70: e19-e21
- Recommendations and guidelines for the treatment of pneumonia in Taiwan.J Microbiol Immunol Infect. 2019; 52: 172-199
- Clinical and microbiological characteristics of purulent and non-purulent cellulitis in hospitalized Taiwanese adults in the era of community-associated methicillin-resistant Staphylococcus aureus.BMC Infect Dis. 2015; 15: 311
- Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model.Arterioscler Thromb Vasc Biol. 2015; 35: 2562-2570
- Ticagrelor reduces thromboinflammatory markers in patients with pneumonia.JACC Basic Transl Sci. 2018; 3: 435-449
Article info
Publication history
Published online: November 13, 2020
Accepted:
October 19,
2020
Received:
October 15,
2020
Identification
Copyright
© 2020 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.
